Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of high-dose conbercept ophthalmic injection for diabetic macular edema
CTR20254442Phase 3Active
- Sponsor
- Chengdu Kanghong Pharmaceutical Group
- Start
- Nov 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of conbercept in diabetic macular edema (DME), sponsored by Chengdu Kanghong Pharmaceutical Group. Started Nov 2025; status: active.
02
Drugs
conbercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20254442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254442.